It is noteworthy that while PSA presently serves as the sole biomarker for prostate cancer, a retrospective analysis of the existing literature indicates that PSA levels may not consistently correlate with the severity of PDA. The gene discussed is KLK3; the disease is Patent ductus arteriosus.